Steven Simonson
Chief Tech/Sci/R&D Officer at WINDTREE THERAPEUTICS, INC.
Net worth: 6 176 $ as of 31/03/2024
Profile
Steven G.
Simonson is currently the Chief Medical Officer & Senior Vice President at Windtree Therapeutics, Inc. He previously worked as the Executive Director-Molecule Development Group at Labcorp Drug Development, Inc. and as the Vice President-Clinical Development at Agennix, Inc. He also held the position of Vice President-Clinical Development at Agennix AG from 2011 to 2012.
Dr. Simonson obtained a doctorate degree from The Medical College of Wisconsin, Inc. and a graduate degree from Duke University School of Medicine.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
16/04/2024 | 17,446 ( 0.21% ) | 6 176 $ | 31/03/2024 |
Steven Simonson active positions
Companies | Position | Start |
---|---|---|
WINDTREE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/10/2014 |
Former positions of Steven Simonson
Companies | Position | End |
---|---|---|
AGENNIX AG | Chief Tech/Sci/R&D Officer | 18/04/2011 |
Agennix, Inc.
Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Corporate Officer/Principal | 01/11/2012 |
COVANCE INC. | Corporate Officer/Principal | - |
Training of Steven Simonson
The Medical College of Wisconsin, Inc. | Doctorate Degree |
Duke University School of Medicine | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
WINDTREE THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Labcorp Drug Development, Inc.
Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
Agennix, Inc.
Agennix, Inc. Pharmaceuticals: MajorHealth Technology Agennix, Inc. develops drugs for the treatment of cancer and wound healing. It develops liquid formulation of talactoferrin for cancer indications and a topical gel formulation for the treatment of diabetic foot ulcers. The company is headquartered in Houston, TX. | Health Technology |
Agennix AG
Agennix AG BiotechnologyHealth Technology Agennix AG was a pharmaceutical company, which engaged in the development of protein-based drugs for oncology, asthma and wound healing. Its clinical development programs included oral talactoferrin alfa and RGB-286638. The company was founded in 1993 and was headquartered in Heidelberg, Germany. | Health Technology |
- Stock Market
- Insiders
- Steven Simonson